左西孟旦配伍新活素对射血分数降低的心力衰竭的影响  

The Effect of Levosimendan Combined with Recombinant Human Brain Natriuretic Peptide on Heart Failure with Reduced Ejection Fraction

作　　者：刘礼敬 陆元喜 胡文标 王琦武[1] 林晓峰[1] 温心 韦佳玲 LIU Lijing;LU Yuanxi;HU Wenbiao;WANG Qiwu;LIN Xiaofeng;WEN Xin;WEI Jialing(Department of Cardiovascular MedicineⅡ,Nanning Second People’s Hospital,Nanning,Guangxi 530031,China)

机构地区：[1]南宁市第二人民医院心血管内科二病区,广西南宁530031

出　　处：《中国医药指南》2025年第11期59-61,共3页Guide of China Medicine

摘　　要：目的观察左西孟旦配伍新活素在射血分数降低的心力衰竭(HFrEF)的作用。方法选取2022年1月至2023年12月在广西南宁市第二人民医院心血管内科二病区治疗的98例HFrEF患者。根据治疗方法分成两组,对照组41例予以新活素治疗,联合组57例予以左西孟旦联合新活素治疗。比较两组的治疗效果,分析治疗前后的左室射血分数(LVEF)、左室收缩末内径(LVESD)、左室短缩率(LVFS)、左室舒张末内径(LVEDD)、血清脑钠肽(BNP)含量,统计治疗不良反应。结果联合组的总有效率高于对照组,前者达96.49%,后者为80.49%(P<0.05)。治疗后,LVEF和LVFS呈现增强趋势,LVESD和LVEDD呈现下降趋势,且联合组LVEF、LVFS高于对照组,LVEDD低于对照组(P<0.05)。此外,BNP水平呈现下降趋势,联合组的BNP水平低于对照组(P<0.05)。两组之间的不良反应发生率差异无统计学意义(P>0.05)。结论左西孟旦配伍新活素在改善HFrEF患者具有显著优势,可提高临床疗效,增强心功能,同时不增加患者的不良反应风险。Objective To observe the efficacy of combination of levosimendan and recombinant human brain natriuretic peptide(rhBNP)in patients with heart failure with reduced ejection fraction(HFrEF).Methods A total of 98 HFrEF patients treated in the Second Ward of the Department of Cardiovascular Medicine at Nanning Second People’s Hospital from January 2022 to December 2023 were selected.Based on treatment methods,they were divided into two groups:the control group(41 cases)received rhBNP treatment,while the combination group(57 cases)received levosimendan combined with rhBNP treatment.The therapeutic effects of the two groups were compared,and the left ventricular ejection fraction(LVEF),left ventricular end-systolic diameter(LVESD),left ventricular fractional shortening(LVFS),left ventricular end-diastolic diameter(LVEDD),and serum brain natriuretic peptide(BNP)levels before and after treatment were analyzed.Adverse reactions were also recorded.Results The combined group’s total effective rate was higher than the control group’s,the former was 96.49%,the latter was 80.49%(P<0.05).After treatment,LVEF and LVFS were increasing,LVESD and LVEDD were decreasing,and combined group’s LVEF and LVFS were higher than control group’s,and LVEDD was lower than control group’s(P<0.05).In addition,BNP levels showed a downward trend,and combined group’s BNP levels were lower than control group’s(P<0.05).There was no significant difference in the incidence of adverse events between the two groups(P>0.05),indicating that the combination treatment regimen did not cause additional safety concerns.Conclusions Levosimendan combined with rhBNP has significant advantages in improving HFrEF patients,improving clinical efficacy and enhancing cardiac function without increasing the risk of adverse events in patients.

关 键 词：射血分数降低的心力衰竭 急性心力衰竭 重组人脑钠肽 左西孟旦 

分 类 号：R541.6[医药卫生—心血管疾病]